Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: A propensity score matching analysis

Chih-Wen Lin

E-DA Hospital, I-Shou University <https://orcid.org/0000-0003-2344-5056>

Yaw-Sen Chen

E-Da Hospital, I-Shou University

Gin-Ho Lo

E-Da hospital, I-Shou University

Yao-Chun Hsu

E-Da hospital, I-Shou University

Chia-Chang Hsu

E-Da hospital, I-Shou University

Tsung-Chin Wu

E-Da Dachang hospital, I-Shou University

Jen-Hao Yeh

E-Da Dachang Hospital, I-Shou University

Pojen Hsiao

E-Da Dachang, I-Shou University

Pei-Min Hsieh

E-Da hospital, I-Shou University

Hung-Yu Lin

E-Da Cancer Hospital, I-Shou University

Chih-Wen Shu

I-Shou University

Chao-Ming Hung (✉ ed1001968@edah.org.tw)

Research article

Keywords: Hepatocellular carcinoma; Barcelona Clinic Liver Cancer stage B; Overall survival; Surgical resection; Transcatheter arterial chemoembolization; Radiofrequency ablation

Posted Date: March 13th, 2020

DOI: <https://doi.org/10.21203/rs.2.22284/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Gastroenterology on April 10th, 2020. See the published version at <https://doi.org/10.1186/s12876-020-01235-w>.

Abstract

Background: Patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) are recommended to undergo transcatheter arterial chemoembolization (TACE). However, TACE in combination with radiofrequency ablation (RFA) is not inferior to surgical resection (SR), and the benefits of surgical resection (SR) for BCLC stage B HCC remain unclear. Hence, this study aims to compare the impact of SR, TACE+RFA, and TACE on analyzing overall survival (OS) in BCLC stage B HCC. **Methods:** Overall, 428 HCC patients were included in BCLC stage B, and their clinical data and OS were recorded. OS was analyzed by the Kaplan-Meier method and Cox regression analysis. **Results:** One hundred forty (32.7%) patients received SR, 231 (53.9%) received TACE+RFA, and 57 (13.3%) received TACE. The OS was significantly higher in the SR group than that in the TACE+RFA group [hazard ratio (HR): 1.78; 95% confidence interval (CI): 1.15-2.75, $p=0.009$]. The OS was significantly higher in the SR group than that in the TACE group (HR: 3.17; 95% CI: 2.31-4.36, $p<0.0001$). Moreover, the OS was significantly higher in the TACE+RFA group than that in the TACE group (HR: 1.82; 95% CI: 1.21-2.74, $p=0.004$). The cumulative OS rates at 1, 3 and 5 years in the SR, TACE+RFA, and TACE groups were 89.2%, 69.4% and 61.2%, 86.0%, 57.9% and 38.2%, and 69.5%, 37.0% and 15.2%, respectively. After propensity score matching, the SR group still had a higher OS than those of the TACE+RFA and TACE groups. The TACE+RFA group had a higher OS than that of the TACE group. **Conclusion:** The SR group had higher OS than the TACE+RFA and TACE groups in BCLC stage B HCC. Furthermore, the TACE+RFA group had higher OS than the TACE group.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer but the third most lethal cancer worldwide[1]. The Barcelona Clinic Liver Cancer (BCLC) system is widely utilized in the American Association for the Study of Liver Disease (AASLD), European Association for the Study of Liver (EASL) and Asian-Pacific Associated for the Study of the Liver (APASL) guidelines for the treatment of HCC[2-4]. Patients with stage B (intermediate stage) HCC are recommended to undergo transcatheter arterial chemoembolization (TACE) based on the BCLC system[2-4]. However, surgical resection (SR) and radiofrequency ablation (RFA) are curative therapies in BCLC stage 0/A and are alternative therapies for selected patients with BCLC stage B in clinical practice[5-7]. Previous studies have shown that TACE combined with RFA (TACE+RFA) has a better overall survival (OS) than TACE in BCLC stage B[6, 8, 9]. Moreover, some studies have shown that SR can have a better OS than TACE with or without RFA in BCLC stage B[5-7]. However, TACE+RFA is not inferior to SR for patients with HCC within the Milan criteria[10]. Furthermore, TACE + RFA is not inferior to SR for patients with HCC within BCLC stage A or B after propensity score-based analysis[6]. Hence, this study aims to compare the impact of SR, TACE + RFA, and TACE on the OS of HCC patients with BCLC stage B. Each patient was treated with one of these three therapies. Furthermore, we compared the OS of patients in each group using propensity score matching (PSM) to minimize potential bias in the results.

Materials And Methods

Patients and follow-up

We retrospectively collected information on 2680 patients diagnosed with HCC between 2011 and 2018 at E-Da Hospital, I-Shou University, Kaohsiung, Taiwan. Two thousand and one hundred forty-six patients were excluded due to BCLC stage 0, A, C, and D, and 110 patients had incomplete data in BCLC stage B. Finally, 428 patients with BCLC stage B were included in this retrospective study (Figure 1). The study was conducted in accordance with the guidelines of the International Conference on Harmonization for Good Clinical Practice and was approved by the Ethics Committee of E-Da Hospital, I-Shou University (EMRP-107-130). Patients were diagnosed with HCC based on histological confirmation or at least one typical imaging method according to the recommendations of the AASLD[2]. Clinicopathological parameters, including demographic data, smoking, excessive alcohol use, hepatitis status, serum total bilirubin, international normalization ratio (INR), liver cirrhosis, Child-Pugh (CP) class, tumor size, tumor number, alpha-fetoprotein (AFP), mortality, and follow-up time, were examined. Tumor number and tumor size were mostly determined based on radiologic findings and confirmed by pathologic findings if appropriate. Liver cirrhosis was diagnosed based on pathologic findings and/or evaluated by ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). The functional status of the liver was evaluated using the CP scoring system.

Patients were treated with SR, TACE+RFA, and TACE, and our multidisciplinary team chose suitable therapy. The criteria for SR were resectable tumors, sufficient residual liver volume, CP class A or selected CP class B patients, or absence of ascites and hypersplenism. The indications of TACE+RFA were CP class A or B and absent ascites. The indications of TACE were CP class A or B and absent massive ascites. Patients were divided into the SR group, TACE+RFA group, and TACE group.

Patients were followed up every three to six months by abdominal ultrasound, CT or MRI and AFP. OS was defined as the time from the date of diagnosis to the date of death or last visit, and the last follow-up time was June 2019.

Data analysis and statistics

All statistical analyses were performed using SPSS ver. 23.0 (SPSS, Chicago, IL, USA). Numerical data were expressed as medians and ranges. Categorical data were described using numbers and percentages. OS was determined using the Kaplan-Meier method and compared with patients receiving different treatments. Cox proportional hazards regression analysis of OS in HCC patients was performed according to different treatments. Moreover, we used logistic regression to perform PSM with sex, age, cirrhosis, CP class, tumor size, and tumor number for patients to reduce bias in our analyses. Each treatment group was matched with the control group (SR group or TACE group) according to the generated PSM using a caliper width of 0.2. On the completion of matching, the baseline covariates were compared using the paired t-test or Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. A p-value <0.05 was used to determine statistical significance.

Results

Baseline demographic data before propensity score matching

A total of 428 HCC patients were included in this study (Figure 1). The demographic and clinical features of the 428 patients (77.8% male, median age of 63 years) are shown in Table 1. Regarding the etiology of HCC, 47.9% of the patients had HBV infection, 32.4% had HCV infection, and 42.3% had excessive alcohol use. Approximately 54.7% of patients had liver cirrhosis, and of those patients, 86.9% had CP class A disease. Many (67.5%) of the patients had tumors ≥ 5 cm in size, and 65.0% of the patients had multiple tumors.

Overall survival of patients in the total and different treatment groups

Of the 428 patients, 257 (60.0%) died, and the median follow-up duration was 29 (range, 1-98) months (Table 1). The mortality rate was 24.8% per person-year. The cumulative OS rates at 1, 3, and 5 years were 80.8%, 50.6% and 32.8%, respectively (Figure 2A). Among the 428 patients, 140 (32.7%) patients received SR, 231 (53.9%) received TACE+RFA, and 57 (13.3%) received TACE (Table 1). The OS was significantly better in the SR group than in the TACE+RFA group (HR: 1.78; 95% CI: 1.15-2.75, $p=0.009$, Figure 2B). The OS was significantly better in the SR group than in the TACE group (HR: 3.17; 95% CI: 2.31-4.36, $p<0.0001$, Figure 2B). Moreover, the OS was significantly better in the TACE+RFA group than in the TACE group (HR: 1.82; 95% CI: 1.21-2.74, $p=0.004$, Figure 2B). The cumulative OS rates at 1, 3 and 5 years in the SR, TACE+RFA, and TACE groups were 89.2%, 69.4% and 61.2%, 86.0%, 57.9% and 38.2%, and 69.5%, 37.0% and 15.2%, respectively (Figure 2B).

Baseline demographic data after propensity score matching

The SR group showed significant differences compared with the TACE+RFA and TACE groups with respect to baseline features before PSM. The SR group had significantly lower rate of HCV infection cirrhosis, tumor number, and mortality, lower serum total bilirubin and INR level, and higher rate of CP class A and tumor size compared to the TACE+RFA and TACE groups ($p<0.05$) (Table 1). The PSM was performed with sex, age, cirrhosis, CP class, tumor size, and tumor number, and there were no significant differences for the important features (Table 2 and 3).

Overall survival of patients in the different treatment groups after propensity score matching

In the SR group versus TACE+RFA group after PSM (Table 2), 140 patients underwent SR, and 16 patients received TACE+RFA. Patients undergoing SR had significantly higher survival rates than patients receiving TACE+RFA (HR: 2.33; 95% CI: 1.21-4.49, $p=0.011$, Figures 3A). The cumulative OS rates at 1, 3 and 5 years in the SR and TACE+RFA groups were 89.2%, 69.4% and 61.2% and 81.3%, 50.0% and 26.8%, respectively (Figures 3A).

In the SR group versus TACE group after PSM (Table 2), 140 patients underwent SR, and 87 patients received TACE. Patients undergoing SR had significantly higher survival rates than patients receiving

TACE treatments (HR: 3.10; 95% CI: 2.15-4.46, $p < 0.0001$, Figures 3B). The cumulative OS rates at 1, 3 and 5 years in the SR and TACE groups were 89.2%, 69.4% and 61.2% and 70.1%, 36.3% and 15.7%, respectively (Figures 3B).

In the TACE+RFA group versus TACE group after PSM (Table 3), 56 patients received TACE+RFA, and 231 patients received TACE. Patients undergoing TACE+RFA had significantly higher survival rates than patients receiving TACE treatments (HR: 1.77; 95% CI: 1.22-2.56, $p = 0.002$, Figures 3C). The cumulative OS rates at 1, 3 and 5 years in the TACE+RFA and TACE groups were 85.7%, 57.1% and 37.7% and 73.5%, 37.0% and 15.2%, respectively (Figures 3C).

Abbreviations

HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; AASLD: American Association for the Study of Liver Disease; EASL: European Association for the Study of Liver; APASL: Asian-Pacific Associated for the Study of the Liver; SR: Surgical resection; RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization; PSM: Propensity score matching; CP class: Child-Pugh class; OS: overall survival; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: Alpha-fetoprotein; INR: International normalize ratio; CT: Computed tomography; MRI: Magnetic resonance imaging; HR: Hazard ratio; and CI: Confidence interval;

Declarations

SPECIFIC AUTHOR CONTRIBUTIONS

Lin CW, Chen YS, Lo GH, Hsu YC and Wu TC performed the experiments, recruited the patients, collected and analyzed the data, and wrote the manuscript together with Hsu CC, Yen JH, Hsiao PJ, Hsieh PM, Lin HY, and Shu CW. Hung CM designed the study and wrote the manuscript together with Lin CW and Chen YS. All of the authors provided important suggestions pertaining to the manuscript and reviewed and approved the manuscript.

ACKNOWLEDGMENTS

This study was supported by grants from MOST (105-2314-B-650-004-MY3 and 108-2314-B-214-006-MY2), the E-Da Hospital-National Taiwan University Hospital Joint Research Program (108-EDN11), and the E-Da Hospital (EDAHP108036, EDAHP108037, ECAHP108038, EDAHP109044, EDAHP109045, and , EDAHP109053) to Chih-Wen Lin.

CONFLICTS OF INTEREST

None declared.

References

1. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, Negri E: **Global trends and predictions in hepatocellular carcinoma mortality.** *J Hepatol* 2017, **67**(2):302-309.
2. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA: **AASLD guidelines for the treatment of hepatocellular carcinoma.** *Hepatology* 2018, **67**(1):358-380.
3. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L: **EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.** *J Hepatol* 2018, **69**(1):182-236.
4. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S *et al*: **Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.** *Hepatol Int* 2017, **11**(4):317-370.
5. Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X, Li LQ: **Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.** *PLoS One* 2013, **8**(7):e68193.
6. Liu Y, Xue D, Tan S, Zhang Q, Yang X, Li Y, Zhu B, Niu S, Jiang L, Wang X: **Comparison of macrovascular invasion-free survival in early-intermediate hepatocellular carcinoma after different interventions: A propensity score-based analysis.** *J Cancer* 2019, **10**(17):4063-4071.
7. Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC, Zhou WP: **Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT.** *J Hepatol* 2014, **61**(1):82-88.
8. Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M *et al*: **Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching.** *Hepatol Res* 2019, **49**(8):919-928.
9. Liu F, Chen M, Mei J, Xu L, Guo R, Lin X, Zhang Y, Peng Z: **Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma.** *J Oncol* 2019, **2019**:6298502.
10. Bholee AK, Peng K, Zhou Z, Chen J, Xu L, Zhang Y, Chen M: **Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study.** *Clin Transl Oncol* 2017, **19**(7):844-852.
11. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B: **Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.** *Semin Liver Dis* 2012, **32**(4):348-359.
12. Forner A, Gilabert M, Bruix J, Raoul JL: **Treatment of intermediate-stage hepatocellular carcinoma.** *Nat Rev Clin Oncol* 2014, **11**(9):525-535.
13. Ho MC, Hasegawa K, Chen XP, Nagano H, Lee YJ, Chau GY, Zhou J, Wang CC, Choi YR, Poon RT *et al*: **Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th**

Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). *Liver Cancer* 2016, 5(4):245-256.

14. Guo H, Wu T, Lu Q, Li M, Guo JY, Shen Y, Wu Z, Nan KJ, Lv Y, Zhang XF: **Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages.** *Cancer Manag Res* 2018, 10:361-369.

Tables

Table 1. Basic demographic data of patients with BCLC stage B hepatocellular carcinoma of various treatments.

Variable	SR (n=140)	TACE (n=231)	TACE+RFA (n=57)	Total (n=428)	P-value
Male	117 (83.6)	173 (74.9)	43 (75.4)	333 (77.8)	0.134
Age (years)	62 (35-82)	64 (29-91)	64 (28-86)	63 (25-91)	0.311
Smoking	68 (48.6)	113 (48.9)	27 (47.4)	208 (48.6)	0.978
Alcohol use	58 (41.4)	100 (43.3)	23 (40.4)	181 (42.3)	0.894
HBV positive	70 (50.0)	103 (44.6)	32 (56.1)	205 (47.9)	0.245
HCV positive	30 (21.4)	90 (39.0)	21 (36.8)	141 (32.9)	0.002
Total Bilirubin	1.03 ± 0.43	1.34 ± 1.14	1.40 ± 0.66	1.24 ± 0.91	0.003
INR	1.00 ± 0.06	1.06 ± 0.12	1.10 ± 0.14	1.05 ± 0.11	<0.0001
Cirrhosis	36 (25.7)	155 (67.1)	43 (75.4)	234 (54.7)	<0.0001
Child-Pugh class A	134 (95.7)	194 (84.0)	44 (77.2)	372 (86.9)	<0.0001
Tumor size	8.2 ± 3.3	7.0 ± 3.8	5.5 ± 2.6	7.0 ± 3.6	0.001
Tumor size ≥ 5 cm	127 (90.7)	149 (64.5)	25 (43.8)	289 (67.5)	<0.0001
Tumor number (≥ 3)	49 (35.0)	178 (77.1)	51 (89.5)	278 (65.0)	<0.0001
AFP (ng/mL) ≥ 200	34 (24.3)	50 (21.6)	7 (12.1)	91 (21.3)	0.171
Mortality	50 (35.7)	173 (74.9)	34 (59.6)	257 (60.0)	<0.0001
Follow-up times (months)	39 (1-98)	22 (1-97)	37 (3-95)	29 (1-98)	<0.001

BCLC stage: Barcelona clinic liver cancer; SR: Surgical resection; TACE: Transcatheter arterial chemoembolization; RFA: Radiofrequency ablation; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: INR: International normalize ratio; Alpha-fetoprotein;

Table 2. Comparison of surgical resection versus transarterial chemoembolization with or without radiofrequency ablation of patients with BCLC stage B hepatocellular carcinoma after propensity score matching

Variable	SR (n=140)	TACE+RFA (n=16)	P-value	SR (n=140)	TACE (n=87)	P-value
Male	117 (83.6)	13 (81.3)	0.220	117 (83.6)	67 (77.0)	0.813
Age (years)	62 (35-82)	66 (35-87)	0.249	62 (35-82)	64 (36-87)	0.121
Smoking	68 (48.6)	8 (50.0)	0.472	68 (48.6)	38 (43.7)	0.914
Alcohol use	58 (41.4)	7 (43.8)	0.858	58 (41.4)	35 (40.2)	0.858
HBV positive	70 (50.0)	10 (62.5)	0.206	70 (50.0)	36 (41.4)	0.343
HCV positive	30 (21.4)	6 (16.7)	0.069	30 (21.4)	26 (29.8)	0.148
Total Bilirubin	1.03 ± 0.43	1.21 ± 0.54	0.186	1.03 ± 0.43	1.11 ± 0.50	0.061
INR	1.00 ± 0.06	1.04 ± 0.10	0.061	1.00 ± 0.06	1.03 ± 0.09	0.051
Cirrhosis	36 (25.7)	6 (37.5)	0.098	36 (25.7)	31 (35.6)	0.111
Child-Pugh class A	134 (95.7)	14 (87.5)	0.236	134 (95.7)	80 (92.7)	0.158
Tumor size	8.2 ± 3.3	6.6 ± 2.8	0.903	8.2 ± 3.3	8.2 ± 3.5	0.063
Tumor size ≥ 5 cm	127 (90.7)	12 (75.0)	0.186	127 (90.7)	75 (86.2)	0.071
Tumor number (≥ 3)	49 (35.0)	9 (56.2)	0.075	49 (35.0)	41 (47.1)	0.058
AFP (ng/mL) ≥ 200	34 (24.3)	2 (12.5)	0.405	34 (24.3)	17 (19.5)	0.289
Mortality	50 (35.7)	11 (68.8)	<0.0001	50 (35.7)	70 (80.5)	0.010
Follow up times (months)	39 (1-98)	26 (9-76)	<0.0001	39 (1-98)	21 (2-97)	0.240

BCLC stage: Barcelona clinic liver cancer; SR: Surgical resection; TACE: Transcatheter arterial chemoembolization; RFA: Radiofrequency ablation; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: International normalize ratio; Alpha-fetoprotein;

Table 3. Comparison of transarterial chemoembolization with radiofrequency ablation versus transarterial chemoembolization of patients with BCLC stage B hepatocellular carcinoma after propensity score matching

Variable	TACE+RFA (n=56)	TACE (n=231)	P-value
Male	42 (75.0)	173 (74.9)	0.987
Age (years)	64 (28-86)	64 (29-91)	0.672
Smoking	27 (47.4)	113 (48.9)	0.925
Alcohol use	23 (40.4)	100 (43.3)	0.763
HBV positive	32 (56.1)	103 (44.6)	0.091
HCV positive	21 (36.8)	90 (39.0)	0.085
Total Bilirubin	1.41 ± 0.67	1.34 ± 1.14	0.643
INR	1.10 ± 0.14	1.06 ± 0.12	0.060
Cirrhosis	43 (75.4)	155 (67.1)	0.160
Child-Pugh class A	43 (76.8)	194 (84.0)	0.203
Tumor size	5.5 ± 2.6	7.0 ± 3.8	0.062
Tumor size ≥ 5 cm	25 (44.6)	149 (64.5)	0.053
Tumor number (≥ 3)	50 (89.3)	178 (77.1)	0.051
AFP (ng/mL) ≥ 200	6 (10.7)	50 (21.6)	0.064
Mortality	34 (59.6)	173 (74.9)	0.034
Follow up times (months)	36 (3-95)	22 (1-97)	<0.0001

BCLC stage: Barcelona clinic liver cancer; SR: Surgical resection; TACE: Transcatheter arterial chemoembolization; RFA: Radiofrequency ablation; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: INR: International normalize ratio; Alpha-fetoprotein;

Figures

Figure 1

Study flowchart and inclusion of participants.

Figure 2

Overall survival in Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma (HCC) patients. Overall survival in all 428 HCC patients (A). Overall survival based on Cox regression analysis in HCC patients with different treatments before propensity score matching (B).

Figure 3

Overall survival according to different treatments after propensity score matching. Comparison of overall survival between surgical resection (SR) versus transarterial chemoembolization (TACE) with radiofrequency ablation (RFA) (A). Comparison of overall survival between SR versus TACE (B). Comparison of overall survival between TACE+RFA versus TACE (C).